Results 171 to 180 of about 8,055 (251)

A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy

Obesity Science &Practice, Volume 12, Issue 5, October 2026.
ABSTRACT Objective High‐potency incretin therapy achieved substantial weight loss, but the extreme energy deficits it induced may obscure the underlying nutritional deterioration. This meta‐analysis synthesized data from 19 randomized trials across the SURMOUNT, STEP, SCALE, and OASIS programs to quantify the nutritional and body composition ...
Eugene Ampofo, Charles Apprey, Mary Amoako, Fiifi Derrick Turkson   +3 more
wiley   +1 more source

GIP/GLP-1 DUAL AGONIST TIRZEPATIDE AMELIORATES RENAL ISCHEMIA/REPERFUSION DAMAGE IN RATS

Objective: Renal Ischemia/Reperfusion Injury (RIRI) initiates a cascade of deleterious events resulting in acute kidney injury with high mortality rates.
ALKHAFAJI, GHADA A., JANABI, ALI M.
core  

Patient‐Reported Continuity of GLP‐1 Receptor Agonist Therapy

Obesity Science &Practice, Volume 12, Issue 5, October 2026.
ABSTRACT Objective Use of GLP‐1 receptor agonists is associated with significant weight loss in many individuals. Discontinuation is associated with weight regain. Patients' experience with this is not well characterized. This study describes the patient experience of continuity of care.
You Chen, Gracie Piantek, Xinmeng Zhang, Yubo Feng, Chao Yan, Jason M. Samuels, S. Trent Rosenbloom, Danxia Yu, Laurie L. Novak, Gitanjali Srivastava   +9 more
wiley   +1 more source

Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Hwang I, Lee SW, Kim Y.
europepmc   +1 more source

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies

Clinical Obesity, Volume 16, Issue 5, October 2026.
ABSTRACT This systematic review and meta‐analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow‐up.
Giovanna Pagani Paccola, Roberta Fernandes de Oliveira, Matheus Menão Mochetti, Fernanda Pataro Marsola Razera, Rafael Vecchi, Renan Canale Peres Montanher   +5 more
wiley   +1 more source

Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series. [PDF]

Obes Pillars
Nadolsky S, Kessel S, Krumm ZA, Tinsley GM.   +3 more
europepmc   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8757-8768, October 2026.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9621-9632, October 2026.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8769-8776, October 2026.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8836-8846, October 2026.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source